Holen Sie sich die Stockscreener-App
15.53
8.32%
-1.41
Handel nachbörslich:
15.70
0.17
+1.09%
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline – Company AnnouncementFT.com - Financial Times
QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class ... - Bluefield Daily Telegraph
uniQure (QURE) Upgraded to Outperform by Mizuho, Price Target Ra - GuruFocus
uniQure upgraded at Mizuho on improved outlook for Huntington's asset AMT-130 - Seeking Alpha
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class ActionHagens Berman - PR Newswire
A Unique Situation For UniQure (QURE) - Seeking Alpha
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
HC Wainwright Has Negative Forecast for uniQure Q1 Earnings - MarketBeat
Atika Capital Management LLC Invests $5.25 Million in uniQure N.V. $QURE - MarketBeat
Lawsuit filed for Investors who lost money with shares of uniQure N.V. (NASDAQ: QURE) - openPR.com
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP - NewMediaWire
QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 – Company AnnouncementFT.com - Financial Times
QURE LAWSUIT ALERT: Levi & Korsinsky Notifies uniQure N.V. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
uniQure (QURE) Gains Momentum with Mizuho's Rating Upgrade and Price Target Raise | QURE Stock News - GuruFocus
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. - GlobeNewswire
Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike—Hims & Hers, Ovintiv, Uniqure In Focus - Sahm
Why Is uniQure Stock Skyrocketing Monday? - Sahm
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $31 to $70 - 富途牛牛
uniQure N.V. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your RightsQURE - Morningstar
uniQure's (QURE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? - Benzinga
uniQure (QURE) Shares Set for Growth Amid Regulatory Changes - GuruFocus
Jefferies Financial Group Inc. Reduces Holdings in uniQure N.V. $QURE - MarketBeat
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
UNIQURE N.V. (QURE) DEADLINE ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline - ACCESS Newswire
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
UniQure N.V. (QURE): RBC Capital Upgrades Rating to Outperform With Significant Upside Potential - 富途牛牛
Forecast brighter for Uniqure with Prasad’s departure? - BioWorld MedTech
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - TMX Newsfile
uniQure (QURE) Stock Soars 36% as FDA’s Vinay Prasad Plans April Exit - MEXC
QURE INVESTOR ALERT: uniQure Faces Securities Class Action - GlobeNewswire
QURE DEADLINE: Investors of uniQure N.V. (QURE) are Encouraged to - The National Law Review
QURE DEADLINE: Investors of uniQure N.V. (QURE) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 13, 2026 - NewMediaWire
Levi & Korsinsky Notifies Shareholders of uniQure N.V.(QURE) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire Inc.
QURE Gains Momentum with Chardan Capital's Increased Price Target | QURE Stock News - GuruFocus
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
What the Options Market Tells Us About uniQure - Benzinga
UniQure (QURE) Shares Surge Following FDA Official's Departure - GuruFocus
Dragomir News: UniQure’s Price Volatility Amidst FDA Comments and Dr. Prasad’s Departure - timothysykes.com
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - Yahoo Finance
uniQure (NASDAQ:QURE) Shares Gap Up After Analyst Upgrade - MarketBeat
Wells Fargo Upgrades uniQure (QURE) with Significant Price Targe - GuruFocus
QURE: RBC Capital Upgrades uniQure with a Significant Price Targ - GuruFocus
Is the FDA sabotaging medical companies? UniQure’s valuation rollercoaster - XTB.com
uniQure stock jolts higher again after FDA biologics chief set to exit - TechStock²
uniQure (QURE) Receives Upgrades and Sees Pre-Market Boost - GuruFocus
Biotech firm stocks rise on FDA vaccine head’s exit (QURE:NASDAQ) - Seeking Alpha
uniQure (NASDAQ:QURE) Raised to "Outperform" at Royal Bank Of Canada - MarketBeat
uniQure (QURE) Stock Surges 36% After FDA Official Vinay Prasad Announces Departure - CoinCentral
uniQure surges following departure of key FDA official - Seeking Alpha
Confusion grows amid uniQure and FDA’s AMT-130 row - The Pharmaletter
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
UniQure leads genetic medicine biotech rally after news of Prasad’s exit - Yahoo Finance
Wells Fargo Upgrades UniQure NV(QURE.US) to Buy Rating, Raises Target Price to $60 - 富途牛牛
QURE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RBC Capital Upgrades uniQure to Outperform From Sector Perform, Adjusts Price Target to $35 From $11, Keeps Speculative Risk - marketscreener.com
uniQure NV Opens Weak with 12.86% Gap Down Amid Market Concerns - Markets Mojo
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline - FinancialContent
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shifting Narrative For uniQure (QURE) As FDA Trial Demands Reshape AMT-130 Expectations - Yahoo Finance
uniQure NV Hits Day Low of $15.51 Amid Price Pressure - Markets Mojo
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):